The potential value of a nasal opioid delivery system, which allows titration of dose against response, has been appreciated since Henderson et al first discussed nasal sufentanil absorption in 1988 1 .
Titrated nasal opioid administration was initially performed using a traditional nasal spray bottle with spray volume of 0.09 ml. This delivered a 4.5 µg dose of fentanyl 50 µg/ml, or a 4.5 mg dose of pethidine 50 mg/ml. In initial studies [2] [3] [4] [5] , a maximum of six sprays were permitted and these were repeated every five or ten minutes until pain was controlled. These trials generated very high workload demands on the nursing staff, who were responsible for supervising patient access to the nasal spray. Striebel et al commented "It would be preferable to have a nasal spray bottle with safety features comparable with those of an intravenous patient controlled analgesia pump 5 ." Such a device has now been designed. This paper describes the design principals and contains a description of its preliminary use in a variety of clinical settings.
CASE HISTORIES
A Patient-Controlled Intra-Nasal Analgesia (PCINA) device (Therapeutic Goods Administration approval number 54005, Figure 1 ) was designed, and is produced commercially by one of the authors (G.O.) (Go Medical, Subiaco, W.A.).
When first introduced into clinical use, the bottle was filled with a limited reservoir dose, considered unlikely to confer any risk of respiratory depression even if administered in full. Subsequently, the bottle has been filled with 200 µg of fentanyl or 200 mg of pethidine (4 ml). Each device had a 0.18 ml chamber that aspirated fluid from the reservoir bottle through fine resistance tubing. The maximal filling rate was confirmed by measuring the weight of the bottle pressed at 1, 2, 3, 4, 5, 6 and 7 minute intervals. A graph was then constructed (Figure 2 ), which confirmed the maximum filling rate of 0.19 ml per four minutes. The bottle of the device was labelled as having a four-minute fill time. Thus, the maximum hourly dose available was 142.5 mg of pethidine or 142.5 µg of fentanyl, although this would only be possible with frequent pressing of the device (i.e. more than 15 demands per hour).
The patient was instructed that, as the dose admini-stered was known to be relatively small (i.e. 9 µg of fentanyl or 9 mg of pethidine), multiple doses might be required to control pain. Patients received no other instructions, or restrictions, with respect to use of the device. A selection of ten patients, representing both inpatient and outpatient pain management in metropolitan and country medical practice, are described to illustrate where the device might be useful in clinical practice. The device was offered to patients in the following settings-chronic pain management (palliative care in outpatient metropolitan and inpatient country hospital settings); postoperative pain management; and other acute pain management (outpatient and inpatient metropolitan hospital care, and trauma retrieval). Clinical notes were kept on all patients and they were invited to comment on the device, its use and effectiveness.
CASE 1 Palliative Care (Chronic Pain Management)
A 53-year-old male patient with metastatic adenocarcinoma of the lung complained of extreme drowsiness when using 60 to 100 mg of oral morphine per day (supplemented by non-steroidal antiinflammatory drugs). The patient was distressed by episodes of intense pain during movement. He was also frustrated by an inability to concentrate during the day and by inadequate pain control. He was unwilling to increase his oral morphine dosage for fear of increased drowsiness.
A PCINA device with fentanyl 9 µg per spray and a four-minute lockout was provided. Pain was reduced within 20 minutes, and after self-administration for 30 to 40 minutes, he was able to achieve good control of these acute exacerbations of pain. Once controlled, the patient found he could often rest for several hours before again being troubled by pain. He gained such good pain control that he chose to stop his oral morphine completely for the following six months. Six months after commencing PCINA he started a program of high-dose chemotherapy and subsequently no longer required nasal fentanyl.
CASE 2 Palliative Care (Chronic Pain Management)
An 83-year-old palliative care patient at a country hospital had severe pain secondary to liver metastases from adenocarcinoma of the bowel. The patient had become very drowsy and sometimes difficult to rouse, while requiring 180 to 200 mg of oral morphine per day to gain reasonable pain control. Both the patient and his relatives complained that his excessive drowsiness made communication difficult. He was given a PCINA device containing fentanyl 9 µg per spray, with a four-minute lockout, and his oral morphine dose was reduced by one third.
During the last two weeks of his life he maintained an oral morphine intake of 100 to 120 mg per day. He became more alert and rapidly adjusted to using nasal fentanyl when walking, showering or performing other procedures which he knew were painful. This gave the patient, his family and his carer the opportunity of an improved quality of life, allowing them to converse and interact, without interference from the debilitating drowsiness the patient had experienced previously. The patient, his family, nursing staff and the general practitioner in the country hospital, all commented that they found the technique very acceptable.
CASE 3 Postoperative Pain Management
A 40-year-old in vitro fertilization patient was initially managed with epidural analgesia following caesarean section. Following removal of the epidural catheter within 24 hours, the patient experienced increased pain and was given a single intramuscular dose of pethidine. The obstetrician and patient then discussed the option of commencing PCINA with pethidine 9 mg per spray and four-minute lockout. During the remainder of that day, the patient used two to three sprays of pethidine over a 20 to 30 minute time period and on each occasion reported adequate control of pain by the third spray. She was able to mobilize freely, and during the next postoperative day she used a similar dose regimen approximately three hourly. By the following day, her requirement had reduced to two sprays about five minutes apart, and this was repeated on four occasions during the subsequent forty-eight hours. The patient commented that the pain over this period was reliably and well relieved with two sprays, and that she felt the availability of patient-controlled analgesia had made her pain more tolerable and enhanced her mobility.
CASE 4 Acute Pain Management for Left Renal Colic
The patient, a 30-year-old multigravid Chinese woman, presented at 20 weeks gestation with classical symptoms and signs of left renal colic. Ultrasound examination confirmed obstruction of the left ureter, probably by a small renal calculus. The patient's pain was initially managed with intramuscular pethidine 100 mg. Although her pain relief was satisfactory for three and a half hours, she complained of dizziness, drowsiness and severe nausea.
On return of the pain, she was given a PCINA device (pethidine 9 mg per spray, four-minute lockout). She found that her pain was adequately relieved after the third spray, although in order to gain more complete relief, she usually administered a fourth dose. On most occasions, this gave good pain control for approximately three hours. She followed a similar regimen five times during the first twenty-four hour period, and on four occasions during the second. The patient particularly appreciated being allowed to take this treatment home. She felt confident that she could control her pain adequately during the night, without having to call her medical practitioner. She also com-mented that the side-effects she had experienced with the intranasal pethidine were less than those after the intramuscular injection, and that she was very satisfied with this method.
CASE 5 Acute Pain Management for Trauma Pain
A 28-year-old male patient with a fractured tibia and fibula required acute pain management during transport. He was prescribed PCINA with fentanyl 9 µg and a four-minute lockout by the country general practitioner. Within 15 to 20 minutes he had obtained good relief of his pain and continued to use the device, as required, for the following three hours during transport to the metropolitan area by the Royal Flying Doctor Service. This proved an effective method of pain relief during transport for this patient, who had no other significant injuries.
CASES 6 TO 10 Acute Pain Management for Burns
A group of five patients in a metropolitan teaching hospital evaluated PCINA with fentanyl 9 µg per spray and four-minute lockout, for events such as showering and burns dressing changes. Most patients used four to five sprays shortly before the event. Those having prolonged care (e.g. dressing changes and washing taking up to one hour) expressed appreciation that they were able to continue treatment throughout. All patients stated that the onset of pain relief was much quicker with this method than their previous management, which had been the Burns Unit standard pain regimen of oral morphine, 20 minutes prior to such events. Most also welcomed feeling more alert within a short time of ceasing the procedure. In contrast, one patient complained that he enjoyed the euphoria associated with treatment with morphine, but failed to experience this with intranasal fentanyl. PCINA also proved acceptable to the nursing staff, although they noted that some patients with burns on the hands, or with general debilitation, required assistance with the activation of the device.
DISCUSSION
Striebal et al have demonstrated that intranasal fentanyl results in higher patient satisfaction than a variety of postoperative parenteral opioid therapies 6 , and is similar to intravenous fentanyl in controlling acute postoperative pain after surgery 3, 7 . After intranasal fentanyl, pain levels decrease within five minutes and by 20 to 60 minutes, efficacy is equal to intravenous fentanyl 3, 7 . This is achieved with an increase in dose requirement of about a third via the nasal route 7 . This is consistent with a bioavailability of 71% after nasal fentanyl 8 .
The PCINA equipment we used contrasts with that available for nasal opioid delivery in previous clinical trials. The development of an effective spray device with a reliable lockout interval, allowed us to conduct a preliminary clinical evaluation in a wide variety of pain management settings. Striebel et al first described the use of a spray bottle with no lockout facility [2] [3] [4] [5] . Repeated use of the bottle every five to ten minutes was accompanied by a recommendation to use six separate, consecutive sprays within a minute. Their trials were therefore limited to clinical settings where nursing staff were reliably available every few minutes, and were usually restricted to a short period of observation and postoperative pain management.
These investigators subsequently modified a Baxter disposable PCA pump to provide a lockout interval 6, 9 . However this device is unable to achieve the same level of fine droplets (80 microns) as the Go Medical PCINA spray device. The modified Baxter pump proved suitable for nasal fentanyl, which is tasteless, but was less satisfactory for pethidine, because a significant amount of the delivered dose drained into the oropharynx, causing a bitter taste. In addition to the lack of an efficient spray, the cost of the Baxter pump, and of modifying it, severely limits its suitability for PCINA in clinical practice. The Go Medical device is expected to be available in the price range of $12-20 depending on its reservoir volume and, to avoid the risk of cross infection, is for singlepatient use only. The device can be easily stored in a standard locked cupboard with other restricted drugs, and should similarly be subject to all appropriate regulatory procedures. To address security concerns, it is produced in either a screw-top version with a tamperevident heat-shrink plastic seal, or a metal crimp-top version which requires a specific crimping tool to reseal it once it is opened. The device carries a label "Keep vertical for 5 minutes after use" to warn about inadequate refilling of the internal demand spray tubing should it be tipped onto its side immediately after use. A deflating bladder, which would prevent air entry under these circumstances, is being investigated.
PCINA with pethidine provides better analgesia than similar doses of subcutaneous pethidine after orthopaedic surgery 5 , and, after hysterectomy, analgesia of comparable quality and almost as rapid onset as intravenous pethidine 4 . In one of these studies, however, 4 of 44 (9%) patients complained of a bitter taste from intranasal pethidine 5 . It is hoped that such problems may be minimized when the Go Medical PCINA device is used with pethidine, since it incorporates a single-spray technique of finer droplet size.
These case reports help demonstrate the wide variety of clinical settings in which this new technology is potentially useful. We plan to continue to evaluate new drug delivery methods, such as PCINA, hoping to demonstrate their safety, efficacy and appeal. The value of PCINA in the control of breakthrough pain in cancer patients has been supported 10 , and postoperative PCINA is as well-accepted by patients as intravenous PCA 7 .
In the postoperative setting for example, recent audits conducted by one of the authors (G.O., unpublished) suggest that more than 75% of patients receiving pain management in some hospitals, still receive intramuscular injections of opioids as their main method of treatment. It is hoped it may prove possible to significantly reduce, or even eliminate, the use of intramuscular injections, replacing these with this inexpensive mode of PCA therapy. In a preliminary study, 19 of 21 patients who selected PCINA as an alternative to intramuscular injection in a hospital ward setting found that the need for intramuscular opioid injection was eliminated. Two found nasal pethidine irritating or difficult to use and changed to intramuscular opioid. Further evaluation suggested fentanyl caused less nasal irritation than pethidine (unpublished). Intranasal PCA is also a potentially attractive alternative for patients ceasing intravenous PCA, continuous epidural analgesia or epidural PCA.
The development of this new equipment creates an opportunity to apply nasal patient controlled analgesia to several pain management settings. More detailed evaluation of this new technology, and blinded comparative studies, will be required to further elucidate its role as an alternative in the armamentarium of pain management techniques.
